RETRACTED: Patient-derived tumor-reactive antibodies as diagnostic markers for ovarian cancer (Retracted Article)

被引:73
|
作者
Taylor, Douglas D. [1 ]
Gercel-Taylor, Cicek [1 ]
Parker, Lynn P. [1 ]
机构
[1] Univ Louisville, Sch Med, Div Gynecol Oncol, Dept Obstet Gynecol & Womens Hlth, Louisville, KY 40292 USA
关键词
Ovarian cancer; Early detection; Autoantibodies; CELL-LINES; P53; PROTEIN; HEPATOCELLULAR-CARCINOMA; IMMUNE-RESPONSE; HIGH-THROUGHPUT; BREAST-CANCER; AUTOANTIBODIES; ANTIGENS; IDENTIFICATION; BIOMARKERS;
D O I
10.1016/j.ygyno.2009.06.031
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective. Most ovarian cancers are diagnosed at advanced stage (67%) and prospects for significant improvement in survival reside in early diagnosis. Our objective was to validate our array assay for the identification of ovarian cancer based on quantitation of tumor-reactive IgG. Methods. The diagnostic array utilizes specific exosome-derived antigens to detect reactive IgG in patient's sera. Specific protein targets were isolated by immunoaffinity from exosomes derived from ovarian tumor cell lines. Sera were obtained from age-matched female volunteers, women with benign ovarian disease and with ovarian cancer. Immunoreactivity was also compared between exosomal proteins and their recombinant counterparts. Results. Sera from ovarian cancer patients exhibited significantly greater immunoreactivities than either normal controls or women with benign disease (both considered negative to all antigens tested). Reactivities with nucleophosmin, cathepsin D, p53, and SSX common antigen for patients with all stages of ovarian cancer were significantly higher than for controls and women with benign ovarian disease. Reactivity with placental type alkaline phosphatase, TAG 72, survivin, NY-ESO-1, GRP78, and Muc16 (CA125) allowed the differentiation between Stage III/IV and early stage ovarian cancer. Conclusions. The quantitation of circulating tumor-reactive IgG can be used to identify the presence of ovarian cancer. The analyses of IgG recognition of specific exosomal antigens allows for the differentiation of women with benign ovarian masses from ovarian cancer, as well as distinguishing early and late stage ovarian cancers. Thus, the quantitative assessment of IgG reactive with specific tumor-derived exosomal proteins can be used as diagnostic markers for ovarian cancer. (C) 2009 Elsevier Inc. All rights reserved.
引用
收藏
页码:112 / 120
页数:9
相关论文
共 50 条
  • [21] RETRACTED: The Effect of PTCH1 on Ovarian Cancer Cell Proliferation and Apoptosis (Retracted Article)
    Zheng, Fang
    Xiao, Xinyi
    Wang, Chunmei
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2019, 34 (02) : 103 - 109
  • [22] RETRACTED: Blockade of ONECUT2 expression in ovarian cancer inhibited tumor cell proliferation, migration, invasion and angiogenesis (Retracted Article)
    Lu, Tongyi
    Wu, Binhua
    Yu, Yunfei
    Zhu, Wenhui
    Zhang, Simin
    Zhang, Yinmei
    Guo, Jiaying
    Deng, Ning
    CANCER SCIENCE, 2018, 109 (07) : 2221 - 2234
  • [23] RETRACTED: Levels and Significance of Tumor Markers and Cytokines in Serum and Peritoneal Lavage Fluid of Patients with Peritoneal Metastasis of Gastric Cancer (Retracted Article)
    Yang, Jianqi
    Cao, Wenmiao
    Xing, Enming
    BIOMED RESEARCH INTERNATIONAL, 2022, 2022
  • [24] RETRACTED: Expression of Lymphocyte-Activation Gene 3 (LAG-3) Immune Checkpoint Receptor Identifies a Tumor-Reactive T Cell Population in the Peripheral Blood of Patients with Colorectal Cancer (Retracted Article)
    Huang, Lefu
    Qiao, Guoliang
    Wu, Jiangping
    Ren, Jun
    MEDICAL SCIENCE MONITOR, 2019, 25 : 3495 - 3502
  • [25] RETRACTED: miR-429 mediates tumor growth and metastasis in colorectal cancer (Retracted Article)
    Han, Yantao
    Zhao, Qian
    Zhou, Jie
    Shi, Rui
    AMERICAN JOURNAL OF CANCER RESEARCH, 2017, 7 (02): : 218 - +
  • [26] RETRACTED: Tim-3 Expression in Cervical Cancer Promotes Tumor Metastasis (Retracted Article)
    Cao, Yang
    Zhou, Xiaoxi
    Huang, Xiaoyuan
    Li, Qinlu
    Gao, Lili
    Jiang, Lijun
    Huang, Mei
    Zhou, Jianfeng
    PLOS ONE, 2013, 8 (01):
  • [27] RETRACTED: The Inhibitory Effect of Doxycycline on Cisplatin-Sensitive and -Resistant Epithelial Ovarian Cancer (Retracted Article)
    Wu, Wei
    Yu, Li-hua
    Ma, Bei
    Xu, Ming-juan
    PLOS ONE, 2014, 9 (03):
  • [28] RETRACTED: CYPA promotes the progression and metastasis of serous ovarian cancer (SOC) in vitro and in vivo (Retracted Article)
    Qi, Zhi-Ying
    Wang, Fang
    Yue, Ying-Ying
    Guo, Xue-Wang
    Guo, Rui-Meng
    Li, Hong-Lin
    Xu, Yan-Ying
    JOURNAL OF OVARIAN RESEARCH, 2019, 12 (01)
  • [29] RETRACTED: Period Analysis of Intraracial Differences in Incidence and Survival Rates in Epithelial Ovarian Cancer (Retracted Article)
    Han, Lili
    Husaiyin, Sulaiya
    Liu, Jing
    Maimaiti, Miherinisha
    Niyazi, Mayinuer
    Li, Li
    COMPUTATIONAL AND MATHEMATICAL METHODS IN MEDICINE, 2021, 2021
  • [30] RETRACTED: Nanoscale drug delivery strategies for therapy of ovarian cancer: conventional vs targeted (Retracted Article)
    Gupta, Swati
    Pathak, Yashwant
    Gupta, Manish K.
    Vyas, Suresh P.
    ARTIFICIAL CELLS NANOMEDICINE AND BIOTECHNOLOGY, 2019, 47 (01) : 4066 - 4088